All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Featured:
During the 63rd ASH Annual Meeting and Exposition, Know AML spoke with Alexander E. Perl, University of Pennsylvania, Philadelphia, US. We asked, What does real-world data tell us about frontline therapy with CPX-351 versus venetoclax + azacitidine?
What does real-world data tell us about frontline therapy with CPX-351 vs Ven + Aza?
Perl begins by discussing recent data on CPX-351 in older patients and available regimens for clinicians to choose from. He goes on to outline the importance of analyzing real-world data, and highlights some studies presented at ASH. Perl explains his study, and remarks that there was no significant difference in overall survival (OS) between the two treatments; however, there were differences in comorbidities and toxicities.